Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Number of items: 21.

Man, Stella, Foster, Julie, Carapuca, Elisabete, Davies, James A, Parker, Alan, Sosabowski, Jane and Hallden, Gunnel 2019. Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Scientific Reports 9 , 12840. 10.1038/s41598-019-49150-9
file

Baker, Alexander, Mundy, Rosie M., Davies, James A., Rizkallah, Pierre and Parker, Alan L. 2019. Human adenovirus type 26 uses sialic acid - bearing glycans as a primary cell entry receptor. Science Advances 5 (9) , eaax3567. 10.1126/sciadv.aax3567
file

Baker, Alexander T., Mundy, Rosie, Davies, James, Rizkillah, Pierre T. and Parker, Alan L. 2019. Adenovirus serotype 26 utilises sialic acid bearing glycans as a primary cell entry receptor. bioRxiv 10.1101/580076
file

Baker, Alexander T., Greenshields-Watson, Alexander, Coughlan, Lynda, Davies, James A., Uusi-Kerttula, Hanni, Cole, David K., Rizkallah, Pierre J. and Parker, Alan L. 2019. Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. Nature Communications 10 (1) , -. 10.1038/s41467-019-08599-y
file

Uusi-Kerttula, Hanni, Davies, James A, Thompson, Jill, Wongthida, Phonphimon, Evgin, Laura, Shim, Kevin G., Bradshaw, Angela, Baker, Alexander T, Rizkallah, Pierre J, Jones, Rachel, Hanna, Louise, Hudson, Emma, Vile, Richard, Chester, John D and Parker, Alan L 2018. Ad5NULL-A20 - a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clinical Cancer Research 24 (17) , pp. 4215-4224. 10.1158/1078-0432.CCR-18-1089
file

Hulin-Curtis, Sarah, Davies, James A., Jones, Rachel, Hudson, Emma, Hanna, Louise, Chester, John D. and Parker, Alan L. 2018. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget 9 (41) , pp. 26328-26341. 10.18632/oncotarget.25242
file

Wang, Eddie C. Y., Pjechova, Marina, Nightingale, Katie, Vlachava, Virginia-Maria, Patel, Mihil, Ruckova, Eva, Forbes, Simone K., Nobre, Luis, Antrobus, Robin, Roberts, Dawn, Fielding, Ceri Alan, Seirafian, Sepehr, Davies, James, Murrell, Isa, Lau, Betty, Wilkie, Gavin S., Suarez, Nicolas M., Stanton, Richard J., Vojtesek, Borivoj, Davison, Andrew, Lehner, Paul J., Weekes, Michael P., Wilkinson, Gavin W. G. and Tomasec, Peter 2018. Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses. Proceedings of the National Academy of Sciences 115 (19) , pp. 4998-5003. 10.1073/pnas.1720950115
file

Man, Y. K. Stella, Davies, James A., Coughlan, Lynda, Pantelidou, Constantia, Blázquez-Moreno, Alfonso, Marshall, John F., Parker, Alan L. and Halldén, Gunnel 2018. The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6 integrins efficiently eliminates pancreatic cancer cells. Molecular Cancer Therapeutics 17 (2) , pp. 575-587. 10.1158/1535-7163.MCT-17-0671
file

Uusi-Kerttula, Hanni, Davies, James, Curtis, Sarah, Chester, John and Parker, Alan 2016. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget 7 (19) , pp. 27926-27937. 10.18632/oncotarget.8545
file

Uusi-Kerttula, Hanni, Hulin-Curtis, Sarah, Davies, James Anthony and Parker, Alan L. 2015. Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses 7 (11) , pp. 6009-6042. 10.3390/v7112923
file

Uusi-Kerttula, Hanni, Legut, Mateusz, Davies, James Anthony, Jones, Rachel, Hudson, Emma, Hanna, Louise, Stanton, Richard James, Chester, John D. and Parker, Alan L. 2015. Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fibre knob domain, and their evaluation as targeted cancer therapies. Human Gene Therapy 26 (5) , pp. 320-329. 10.1089/hum.2015.015
file

Seirafian, Sepher, Prod'homme, Virginie, Sugrue, Daniel M., Davies, James, Fielding, Ceri Alan, Tomasec, Peter and Wilkinson, Gavin William Grahame 2014. Human cytomegalovirus suppresses Fas expression and function. Journal of General Virology 95 (4) , pp. 933-939. 10.1099/vir.0.058313-0
file

Fielding, Ceri Alan, Seirafian, Sepher, Davies, James Anthony, Cuff, Simone, Aicheler, Rebecca, Sugrue, Daniel M., Davison, A., Stanton, Richard James, Wilkinson, Gavin William Grahame and Tomasec, Peter 2012. A novel human cytomegalovirus gene function targets the natural killer cell activating ligand MICA for lysosomal degradation [Abstract]. Immunology 137 (S1) , p. 154. 10.1111/imm.12001

Davies, James Anthony, Hathaway, Lee Sarah, Collins, Peter William and Bowen, Derrick John 2012. von Willebrand factor: demographics of plasma protein level in a large blood donor cohort from South Wales in the United Kingdom [Letter]. Haemophilia 18 (3) , e79-e81. 10.1111/j.1365-2516.2012.02782.x

Raby, Anne-Catherine, Holst, Benjamin, Davies, James Anthony, Colmont, Chantal Sophie, Laumonnier, Yves, Coles, Barbara, Shah, Sanjoy, Hall, Judith Elizabeth, Topley, Nicholas, Köhl, Jörg, Morgan, Bryan Paul and Labeta, Mario Oscar 2011. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. European Journal of Immunology 41 (9) , pp. 2741-2752. 10.1002/eji.201041350
file

Stanton, Richard James, Baluchova, Katarina, Dargan, Derrick J., Cunningham, Charles, Sheehy, Orla, Seirafian, Sepher, McSharry, Brian P., Neale, Margaret Lynne, Davies, James Anthony, Tomasec, Peter, Davison, Andrew J. and Wilkinson, Gavin William Grahame 2010. Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. Journal of Clinical Investigation 120 (9) , pp. 3191-3208. 10.1172/JCI42955
file

Prod'homme, Virginie, Sugrue, Daniel M., Stanton, Richard James, Nomoto, A., Davies, James Anthony, Rickards, Carole R., Cochrane, Daniel, Moore, Melanie, Wilkinson, Gavin William Grahame and Tomasec, Peter 2010. Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. Journal of General Virology 91 (8) , pp. 2034-2039. 10.1099/vir.0.021931-0

Raby, Anne-Catherine, Le Bouder, Emmanuel, Colmont, Chantal Sophie, Davies, James Anthony, Richards, Peter, Coles, Barbara, George, Christopher H., Jones, Simon Arnett, Brennan, Paul, Topley, Nicholas and Labeta, Mario Oscar 2009. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. The Journal of Immunology 183 (1) , pp. 506-517. 10.4049/jimmunol.0802909

Davies, James Anthony and Bowen, Derrick John 2007. The association between the L1565 variant of von Willebrand factor and susceptibility to proteolysis by ADAMTS13. Haematologica 92 (2) , pp. 240-243. 10.3324/haematol.10633

Davies, James Anthony, Collins, Peter William, Hathaway, Lee Sarah and Bowen, Derrick John 2007. von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group. Journal of Thrombosis and Haemostatis 6 (1) , pp. 97-103. 10.1111/j.1538-7836.2007.02809.x

Davies, James Anthony, Collins, Peter William, Hathaway, Lee Sarah and Bowen, Derrick John 2006. The effect of von Willebrand factor Y/C1584 on in vivo protein level and function, and interaction with ABO blood group. Blood 109 (7) , pp. 2840-2846. 10.1182/blood-2006-07-035105

This list was generated on Tue Dec 10 04:48:52 2019 GMT.